agents and partners 

At Charles River, our goal is to provide clients with a wide range of services that meet their regulatory and scientific needs.

To address the growing biopharmaceutical market, BPS has enlisted the following agents in Australia, India, Israel, Korea, Singapore and Taiwan. As a global organization, BPS can provide you with more flexibility, experience and expertise in multiple regulatory environments to accelerate the development of your biologic, enabling you to get your product to market faster.

• Australia - Guyan Solutions

• India - Zelle Biotechnology Private Limited
• Israel - Hy Laboratories Ltd.
• Korea - Sartorius Korea Biotech
• Singapore - BRASS™
• Taiwan - LifeOptimal Technology, Inc.

The following partnerships enhance our ability to exceed client expectations by offering cost-effective, innovative solutions that accelerate the production and safety assessment of biopharmaceutical products.

• Millipore: EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, is partnering with Charles River to exclusively license EMD Millipore's TrueSpike™ technology. Together, we will collaborate to integrate the TrueSpike™ technology into client-specified viral clearance projects, to result in a more predictable and consistent study outcome for clients, and ultimately help to improve drug product safety.
• Protagen: Charles River and Protagen Protein Services GmbH, a GMP-certified specialist in the characterization of protein drugs, announced a strategic partnership to provide clients with services covering the entire range of protein analytics, from detailed protein characterization to stability and lot release testing.
• GENEWIZ, Inc.: Our partnership with GENEWIZ, Inc. allows clients to benefit from Charles River's expertise and experience in cell and viral bank characterization with the added option of GENEWIZ's industry-leading Next Generation Sequencing services.
• Batavia Bioservices:  Working together, Charles River and Batavia provide a single point of contact offering a seamless transition from cell line development through to cell banking, characterization, and clinical scale manufacturing of recombinant proteins, mAbs, gene therapies and virus products.